Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/32366
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRedant, Sebastien-
dc.contributor.authorWarrillow, Stephen J-
dc.contributor.authorHonoré, Patrick M-
dc.date.accessioned2023-03-22T02:18:54Z-
dc.date.available2023-03-22T02:18:54Z-
dc.date.issued2023-03-01-
dc.identifier.citationCurrent opinion in clinical nutrition and metabolic care 2023; 26(2): 160-166en_US
dc.identifier.issn1473-6519-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/32366-
dc.description.abstractHyperammonaemia is almost always develops in patients with severe liver failure and this remains the commonest cause of elevated ammonia concentrations in the ICU. Nonhepatic hyperammonaemia in ICU presents diagnostic and management challenges for treating clinicians. Nutritional and metabolic factors play an important role in the cause and management of these complex disorders. Nonhepatic hyperammonaemia causes such as drugs, infection and inborn errors of metabolism may be unfamiliar to clinicians and risk being overlooked. Although cirrhotic patients may tolerate marked elevations in ammonia, other causes of acute severe hyperammonaemia may result in fatal cerebral oedema. Any coma of unclear cause should prompt urgent measurement of ammonia and severe elevations warrant immediate protective measures as well as treatments such as renal replacement therapy to avoid life-threatening neurological injury. The current review explores important clinical considerations, the approach to testing and key treatment principles that may prevent progressive neurological damage and improve outcomes for patients with hyperammonaemia, especially from nonhepatic causes.en_US
dc.language.isoeng-
dc.titleAmmonia and nutritional therapy in the critically ill: when to worry, when to test and how to treat?en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleCurrent opinion in clinical nutrition and metabolic careen_US
dc.identifier.affiliationDepartment of Intensive Care, Brugmann University Hospital, Université Libre de Bruxelles (ULB), Brussels, Belgium.en_US
dc.identifier.affiliationUniversity of Melbourne, Melbourne, Victoria, Australia.en_US
dc.identifier.affiliationDepartment of Intensive Care, Brugmann University Hospital, Université Libre de Bruxelles (ULB), Brussels, Belgium.en_US
dc.identifier.affiliationIntensive Careen_US
dc.identifier.doi10.1097/MCO.0000000000000899en_US
dc.type.contentTexten_US
dc.identifier.pubmedid36892962-
dc.description.volume26-
dc.description.issue2-
dc.description.startpage160-
dc.description.endpage166-
dc.subject.meshtermssecondaryHyperammonemia/etiology-
dc.subject.meshtermssecondaryHyperammonemia/therapy-
dc.subject.meshtermssecondaryAmmonia/metabolism-
dc.subject.meshtermssecondaryCritical Illness/therapy-
local.name.researcherWarrillow, Stephen J
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
crisitem.author.deptIntensive Care-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

110
checked on Nov 22, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.